Femasys Inc.

FEMY ·Healthcare, Medical Devices, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-18.6M $-18.8M $-14.2M $-11.4M $-7.5M $-6.9M
Depreciation & Amortization $342.0K $297.3K $483.5K $561.2K $591.1K $679.7K
Depreciation $295.9K $277.2K $480.2K $539.4K $551.1K $560.8K
Amortization $46.2K $20.1K $3.3K $21.8K $40.0K $118.9K
Stock-Based Compensation $790.1K $444.1K $675.7K $224.9K $193.4K $318.6K
Net Cash from Operating Activities $-18.7M $-19.4M $-11.3M $-10.7M $-7.9M $-4.9M
Investing Activities
Capital Expenditures $525.0K $761.7K $143.9K $407.5K $306.9K $8.4K
Business Acquisitions
Net Cash from Investing Activities $-630.1K $-847.8K $-143.9K $-407.5K $-306.9K $968.3K
Financing Activities
Dividends Paid
Stock Repurchases $60.8K $230.0K $0
Net Cash from Financing Activities $25.1M $2.0M $20.2M $-681.6K $29.7M $871.6K
Net Change in Cash
Free Cash Flow $-19.2M $-20.2M $-11.4M $-11.1M $-8.2M $-4.9M